Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $16.87, but opened at $16.50. Centessa Pharmaceuticals shares last traded at $17.08, with a volume of 356,321 shares traded.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Guggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Finally, Morgan Stanley restated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $26.00.
Check Out Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Price Performance
The stock has a fifty day moving average of $16.45 and a 200-day moving average of $16.36. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -10.79 and a beta of 1.54.
Insider Activity at Centessa Pharmaceuticals
In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total value of $97,080.00. Following the completion of the sale, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,705,145.48. This represents a 5.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $17.44, for a total value of $959,200.00. Following the completion of the sale, the chief executive officer now directly owns 520,661 shares of the company's stock, valued at $9,080,327.84. The trade was a 9.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 247,168 shares of company stock valued at $4,138,928 over the last three months. 11.59% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Centessa Pharmaceuticals
Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $31,000. GAMMA Investing LLC boosted its holdings in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after acquiring an additional 865 shares during the period. Barclays PLC boosted its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $171,000. 82.01% of the stock is owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
